NICE has recommended Ninlaro (ixazomib) with lenalidomide and dexamethasone as an option relapsed or refractory multiple myeloma (RRMM) in adults who have received two or three lines of therapy. Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has been used to treat over 4,000 patients in England. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
